Swiss pharma giant Roche Holding AG RHHBY posted strong growth in the first quarter of 2025. Sales increased 7% year over ...

Roche is working to mitigate potential impacts from tariffs by moving production of its medicines to the U.S. and petitioning ...

Roche is pledging to invest $50 billion in manufacturing and research infrastructure in the U.S. over the next five years, ...

Roche’s Genentech unit and Repertoire Immune Medicines have entered into a partnership worth $765m to discover and develop T ...

The biopharmaceutical industry is positioned for continued recovery, driven by recent FDA approvals and billion-dollar ...

Roche's strong U.S. presence and diversified product portfolio may mitigate the impact of potential tariffs, making it a ...

Global Data has revealed that the Top 20 Global Biopharmaceutical Companies have witnessed a 6 % growth in market ...

Roche's move for the asset comes shortly after Zealand started the phase 2b ZUPREME-1 trial of petrelintide in people overweight or obese, and ahead of the ZUPREME-2 study in overweight or obese ...

The deal will see the two companies co-develop and co-commercialize petrelintide, Zealand Pharma's amylin analog as a standalone therapy, as well as a fixed-dose combination with Roche's lead inc ...

ZURICH, April 22 (Reuters) - Roche (ROG.S), opens new tab said on Tuesday it would invest $50 billion in the United States over the next five years, creating more than 12,000 new jobs, in the ...

The deal terms make Roche responsible for manufacturing and supplying that engineered peptide, petrelintide. Once the new and expanded manufacturing capacity comes online, Roche said the company ...

Roche projected that its $50 billion manufacturing investment, to include R&D operations, will generate 1,000 jobs at the ...